Biomedical subjects

Christian Madsen

Publications and source records attributed to Christian Madsen.

4 recordsLinked to original sources

PubMed2006

Associations between environmental exposure and blood pressure among participants in the Oslo Health Study (HUBRO).

BACKGROUND: It is well known that environmental conditions are related to the risk of developing cardiovascular diseases and events. However, the mechanisms behind these relations are not well understood. One mechanism could be elevation of blood pressure. In this study we assessed associations between blood pressure and environmental conditions among citizens in Oslo, Norway. MATERIALS AND METHODS: We used the Oslo Health Study (HUBRO), a population based study of 18,770 Oslo citizens, to assess associations between blood pressure and environmental conditions including season, smoking, outdoor temperature and air pollution. RESULTS: Blood pressure was higher in the winter season, but the association disappeared when we adjusted for temperature. A 10 degrees C reduction in outdoor temperature, the day blood pressure was measured was related to an increase in blood pressure for both men [SBP: 1.5 mmHg (95% CI, 0.6-2.3); DBP: 1.3 mmHg (95% CI, 0.1-1.8)] and women [SBP: 2.4 mmHg (95% CI, 1.6-3.2); DBP: 1.8 mmHg (95% CI, 1.3-2.3)]. No convincing relation was found between indicators of air pollution exposure and blood pressure. CONCLUSION: Several environmental conditions were related to blood pressure, and have similar associations with cardiovascular diseases or mortality. This could indicate that some of the effect these exposures have on the cardiovascular system is by increasing blood pressure.

Adult↗

PubMed2005

Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling.

We have previously described a series of competitive GABA(A) antagonists derived from the low-efficacy partial agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 4). The 2-naphthylmethyl analogue, 4-(2-naphthylmethyl)-5-(4-piperidyl)-3-isoxazolol (5), provided affinity for the GABA(A) receptor site higher than that of the standard GABA(A) receptor antagonist, SR 95531 (3). Molecular modeling studies of these compounds exposed a cavity at the receptor recognition site capable of accommodating aromatic groups of substantial size in the 4-position in the 3-isoxazolol ring. Here we present a series of analogues of 5, with various substituents in different positions in the naphthyl ring system (6a-k), and compounds with aromatic substituents directly attached to the 4-position of the 3-isoxazolol ring (7l-n). The compounds have been pharmacologically characterized using receptor-binding assays and electrophysiological whole-cell patch-clamp techniques. All of the tested compounds show affinity for the GABA(A) receptor site. While the 5-, 7-, and 8-bromo analogues, 6b-d, showed receptor affinities (K(i) = 45, 109, and 80 nM, respectively) comparable with that of 5 (K(i) = 49 nM), the 1-bromo analogue, 6a, provided the highest receptor affinity of the series (K(i) = 10 nM). Introduction of a series of different substituents in the 1-position in the 2-naphthyl ring system led to compounds, 6e-k, with retained high affinity for the GABA(A) receptor (K(i) = 16-250 nM). Introduction of a phenyl ring directly into the 4-position on the 3-isoxazolol ring gave a 41-fold increase in affinity relative to that of 4-PIOL. In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABA(A) agonist isoguvacine, 6a showing antagonist potency (IC(50) = 42 nM) markedly higher than that of 3 (IC(50) = 240 nM). Molecular modeling studies, based on the compounds described, emphasized the importance of the distal ring in 5 for receptor affinity and the considerable dimensions of the proposed receptor cavity. Furthermore, the phenyl rings in 7l and in 6k were shown to represent highly favorable positions for an aromatic ring in previously unexplored receptor regions in terms of a pharmacophore model.

Animals↗

PubMed2005

Older is wiser.

Explore the source record for details and available documents.

Ambulatory Care Information Systems↗

PubMed2004

Preparation and antiviral properties of new acyclic, achiral nucleoside analogues: 1- or 9-[3-hydroxy-2-(hydroxymethyl)prop-1-enyl]nucleobases and 1- or 9-[2,3-dihydroxy-2-(hydroxymethyl)propyl]nucleobases.

Acyclic, achiral nucleoside derivatives 1b-e of adenine, cytosine, 5-methylcytosine, and guanine, containing a 3-hydroxy-2-(hydroxymethyl)prop-1-enyl group on N-1 or N-9, have been prepared analogously to the previously described thymine derivative 1a. In contrast to the adenine and guanine derivatives, the cytosine derivative 9 was unstable, and was obtained in a low yield due to side reactions. These include cleavage of the propenyl group from the base, and the formation of a bicyclic compound. The thymine derivative, although stable under neutral conditions, likewise underwent a reversible cyclization reaction (Michael addition) in the presence of acids or bases. The 5-methylcytosine derivative was stable under neutral and basic conditions. Four other nucleoside derivatives 26a-d containing a 2,3-dihydroxy-2-(hydroxymethyl)propyl group on N-1 or N-9, three of which are new, have likewise been prepared. All compounds were evaluated as antiviral agents against HIV-1 and HSV-1 but were devoid of antiviral activity.

Adenine↗